Breaking News Instant updates and real-time market news.

REGN

Regeneron

$356.59

-6.66 (-1.83%)

, SNY

Sanofi

$45.50

0.5 (1.11%)

13:36
11/11/18
11/11
13:36
11/11/18
13:36

Regeneron, Sanofi announce new analyses on mortality from ODYSSEY outcomes trial

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that new analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association Scientific Sessions 2018. Praluent Injection was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina, and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C of 100 mg/dL or higher at baseline. Moreover, additional new analyses showed an association between reduced non-fatal cardiovascular events and reduction in non-CV death during the trial period. In the trial, Praluent added to maximally-tolerated statins was compared to maximally-tolerated statins alone in patients who had experienced an ACS within the last 12 months. Data published in the New England Journal of Medicine last week found Praluent significantly reduced the risk of major adverse CV events and was associated with a lower risk of death from any cause. In pre-specified analyses of 8,242 patients followed for at least 3 years, Praluent was associated with a 22% lower risk of death from any cause. Separate post-hoc analyses showed Praluent-treated patients whose baseline LDL-C levels were at or above 100 mg/dL experienced a 29% lower risk of death from any cause. In additional post-hoc analyses, researchers found Praluent-treated patients experienced fewer non-fatal CV events and were less likely to die from a non-CV event, and that these two findings may be associated. No new safety signals were found in the analyses. In ODYSSEY OUTCOMES, the incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions. The effect of Praluent on CV morbidity and mortality is currently being reviewed by regulatory authorities and has not yet been fully evaluated. Data from the ODYSSEY OUTCOMES trial have been submitted to regulatory authorities in the European Union and in the U.S., where the target action date for the Food and Drug Administration decision is April 28, 2019.

REGN

Regeneron

$356.59

-6.66 (-1.83%)

SNY

Sanofi

$45.50

0.5 (1.11%)

  • 11

    Nov

  • 15

    Nov

  • 27

    Nov

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$356.59

-6.66 (-1.83%)

10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
11/06/18
PIPR
11/06/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron operational performance, diversifying pipeline on display in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and $450 price target on Regeneron's shares following Q3 top- and bottom-line beats. The analyst notes that over the last five quarters including Q3, EPS has beaten consensus on average by 55c, consistently driven by top-line beats. Combining strong operational performance with continued pipeline maturation and commercial momentum, the analyst continues to like the setup and remains a buyer.
SNY Sanofi
$45.50

0.5 (1.11%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
11/01/18
LEHM
11/01/18
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Sanofi to Equal Weight and raised his price target for the shares to EUR 80 from EUR 68 following the company's Q3 results. The analyst sees a more balanced risk/reward profile at current share levels.
11/01/18
11/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) upgraded to Outperform from Market Perform at Barrington and to Neutral from Underperform at DA Davidson. 2. SeaWorld (SEAS) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress saying de-risked expectations following the Q3 pre-announcement create an attractive entry point, as he sees further upside to shares, with his confidence in the company's turnaround bolstered by additional evidence of both a brand and business in recovery mode. 3. Sanofi (SNY) upgraded to Equal Weight from Underweight at Barclays with analyst Emmanuel Papadakis saying he sees a more balanced risk/reward profile at current share levels. 4. Asur (ASR) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla citing valuation. 5. Wex (WEX) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SQM

SQM

$37.08

-0.99 (-2.60%)

21:36
04/22/19
04/22
21:36
04/22/19
21:36
Initiation
SQM initiated  »

SQM initiated with a Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NEE

NextEra Energy

$190.53

1.21 (0.64%)

, UTX

United Technologies

$136.99

-0.01 (-0.01%)

20:25
04/22/19
04/22
20:25
04/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEE

NextEra Energy

$190.53

1.21 (0.64%)

UTX

United Technologies

$136.99

-0.01 (-0.01%)

KO

Coca-Cola

$47.38

-0.11 (-0.23%)

VZ

Verizon

$58.38

0.33 (0.57%)

PG

Procter & Gamble

$106.04

-0.01 (-0.01%)

LMT

Lockheed Martin

$315.24

0.94 (0.30%)

SHW

Sherwin-Williams

$451.83

-0.61 (-0.13%)

TWTR

Twitter

$34.39

-0.01 (-0.03%)

STT

State Street

$69.92

-0.02 (-0.03%)

CNC

Centene

$48.19

0.04 (0.08%)

FITB

Fifth Third

$27.54

0.02 (0.07%)

NUE

Nucor

$57.00

-0.49 (-0.85%)

DGX

Quest Diagnostics

$85.17

-0.55 (-0.64%)

HAS

Hasbro

$88.02

-0.72 (-0.81%)

HOG

Harley-Davidson

$39.71

-1.2 (-2.93%)

PII

Polaris Industries

$98.93

0.185 (0.19%)

JBLU

JetBlue

$16.84

-0.13 (-0.77%)

GPK

Graphic Packaging

$12.98

0.035 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 04

    May

  • 07

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 14

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 20

    May

  • 20

    May

  • 22

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 11

    Jun

  • 12

    Jun

  • 23

    Jun

  • 13

    Nov

LOGC

LogicBio Therapeutics

$12.28

0.15 (1.24%)

20:16
04/22/19
04/22
20:16
04/22/19
20:16
Hot Stocks
LogicBio Therapeutics' methylmalonic acidemia treatment gets FDA orphan status »

The FDA has grated an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

RBB

RBB Bancorp

$19.18

-0.61 (-3.08%)

19:38
04/22/19
04/22
19:38
04/22/19
19:38
Earnings
RBB Bancorp reports Q1 EPS 51c, consensus 55c »

Reports Q1 NII $25.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

BEN

Franklin Resources

$35.04

-0.27 (-0.76%)

19:09
04/22/19
04/22
19:09
04/22/19
19:09
Periodicals
Franklin Resources to reduce workforce by up to 5%, Bloomberg says »

Franklin Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

TSLA

Tesla

$262.90

-10.35 (-3.79%)

18:59
04/22/19
04/22
18:59
04/22/19
18:59
Periodicals
Consumer Reports: Tesla 'Autopilot' is no substitute for a human driver »

Consumer Reports states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

CMRE

Costamare

$5.65

-0.09 (-1.57%)

, WHR

Whirlpool

$139.39

0.35 (0.25%)

18:56
04/22/19
04/22
18:56
04/22/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CMRE

Costamare

$5.65

-0.09 (-1.57%)

WHR

Whirlpool

$139.39

0.35 (0.25%)

CDNS

Cadence Design

$64.23

0.87 (1.37%)

BEDU

Bright Scholar

$11.38

-0.105 (-0.91%)

RRC

Range Resources

$9.83

0.07 (0.72%)

WAL

Western Alliance

$43.36

-0.89 (-2.01%)

ALDR

Alder Biopharmaceuticals

$12.77

0.1 (0.79%)

ROKU

Roku

$58.19

1.5 (2.65%)

VCYT

Veracyte

$23.04

0.02 (0.09%)

HARP

Harpoon Therapeutics

$11.35

-1.68 (-12.89%)

RMBS

Rambus

$11.80

-0.1 (-0.84%)

GRTS

Gritstone Oncology

$14.57

0.86 (6.27%)

GES

Guess

$16.66

-0.41 (-2.40%)

BHP

BHP Group

$55.14

0.19 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 04

    May

  • 08

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 22

    May

  • 22

    May

  • 05

    Jun

  • 25

    Apr

PCG

PG&E

$21.45

0.435 (2.07%)

18:52
04/22/19
04/22
18:52
04/22/19
18:52
Hot Stocks
PG&E submits updated financing proposal for safety, reliability investments »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:40
04/22/19
04/22
18:40
04/22/19
18:40
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PCG

PG&E

$21.45

0.435 (2.07%)

18:39
04/22/19
04/22
18:39
04/22/19
18:39
Hot Stocks
PG&E names Fred Buckman to board, expands board to 15 directors »

PG&E Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$204.62

0.79 (0.39%)

18:36
04/22/19
04/22
18:36
04/22/19
18:36
Periodicals
Apple sued for $1B by teen claiming glitch in facial recognition software »

The report by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

GOOG

Alphabet

$1,248.96

11.74 (0.95%)

, GOOGL

Alphabet Class A

$1,253.94

12.01 (0.97%)

18:36
04/22/19
04/22
18:36
04/22/19
18:36
Periodicals
Google walkout organizers say company retaliated against them, Wired says »

Two employee activists at…

GOOG

Alphabet

$1,248.96

11.74 (0.95%)

GOOGL

Alphabet Class A

$1,253.94

12.01 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    Apr

  • 14

    May

  • 27

    Oct

CTRA

Contura Energy

$56.27

0.5 (0.90%)

18:16
04/22/19
04/22
18:16
04/22/19
18:16
Hot Stocks
Contura Energy announces departure of CEO Kevin Crutchfield »

Contura Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

BWEN

Broadwind Energy

$1.88

0.06 (3.30%)

18:04
04/22/19
04/22
18:04
04/22/19
18:04
Hot Stocks
Broadwind Energy announces $19.5M tower order »

Broadwind Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 26

    Apr

HLX

Helix Energy

$8.59

0.2 (2.38%)

18:04
04/22/19
04/22
18:04
04/22/19
18:04
Earnings
Helix Energy reports Q1 adjusted EPS 1c, consensus 0c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 15

    May

VBTX

Veritex

$25.92

-0.3 (-1.14%)

18:03
04/22/19
04/22
18:03
04/22/19
18:03
Earnings
Veritex reports Q1 diluted operating EPS 59c, consensus 55c »

Net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 21

    May

BCS

Barclays

$8.70

-0.05 (-0.57%)

18:00
04/22/19
04/22
18:00
04/22/19
18:00
Periodicals
Barclays planning to slash bonuses for investment bankers, FT says »

Barclays plans to crack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    Jun

NVDA

Nvidia

$188.48

2.22 (1.19%)

, TSLA

Tesla

$262.90

-10.35 (-3.79%)

17:53
04/22/19
04/22
17:53
04/22/19
17:53
Periodicals
Nvidia calls Tesla claims on self-driving 'inaccurate', MarketWatch says »

Tesla (TSLA) claims that…

NVDA

Nvidia

$188.48

2.22 (1.19%)

TSLA

Tesla

$262.90

-10.35 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 22

    May

  • 10

    Jun

EFSC

Enterprise Financial

$42.49

-1.4 (-3.19%)

17:47
04/22/19
04/22
17:47
04/22/19
17:47
Hot Stocks
Enterprise Financial board raised dividend to 15c per share »

The company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

EFSC

Enterprise Financial

$42.49

-1.4 (-3.19%)

17:46
04/22/19
04/22
17:46
04/22/19
17:46
Earnings
Enterprise Financial reports Q1 EPS 67c, consensus 91c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

17:45
04/22/19
04/22
17:45
04/22/19
17:45
General news
U.S. tax refunds »

U.S. tax refunds are on…

BPRN

Bank of Princeton

$32.30

(0.00%)

17:43
04/22/19
04/22
17:43
04/22/19
17:43
Earnings
Bank of Princeton reports Q1 EPS 3c, may not compare to consensus 53c »

Reports Q1 NII $9.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

LENS

Presbia

$0.56

-0.0034 (-0.61%)

17:29
04/22/19
04/22
17:29
04/22/19
17:29
Hot Stocks
Presbia discloses staff reduction, search for investor or strategic partner »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$43.36

-0.89 (-2.01%)

17:23
04/22/19
04/22
17:23
04/22/19
17:23
Earnings
Western Alliance reports Q1 adjusted EPS $1.16, consensus $1.09 »

Reports Q1 NII $247.3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

FCF

First Commonwealth

$13.26

-0.22 (-1.63%)

, SAN

Banco Santander

$5.12

-0.015 (-0.29%)

17:21
04/22/19
04/22
17:21
04/22/19
17:21
Hot Stocks
First Commonwealth to acquire 14 branches from Santander »

First Commonwealth…

FCF

First Commonwealth

$13.26

-0.22 (-1.63%)

SAN

Banco Santander

$5.12

-0.015 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.